SIMILAR PATTERN OF AMINO ACIDS MAPPED TO 'AQD'


List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)
Filter list by:
DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 Interface HETATM RMSD Dali
Z-score		 Seq.
Identity (%)		 View Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1YAJ_G_BEZG3385_0
(CES1 PROTEIN)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		3 / 3 SER A 441
VAL A  87
LEU A  88
 NA  A1224 (-3.5A)
AQD  A1201 ( 4.6A)
None
 0.75A 1yajG-5wivA:
undetectable		 1yajG-5wivA:
22.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1YVP_A_ACTA2001_0
(60-KDA SS-A/RO
RIBONUCLEOPROTEIN)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		4 / 5 TYR A 192
SER A 200
SER A 196
THR A 120
 None
AQD  A1201 (-3.6A)
AQD  A1201 (-2.8A)
AQD  A1201 (-4.4A)
 1.32A 1yvpA-5wivA:
undetectable		 1yvpA-5wivA:
22.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z9H_A_IMNA379_1
(MEMBRANE-ASSOCIATED
PROSTAGLANDIN E
SYNTHASE-2)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		5 / 12 THR A 120
CYH A 119
PRO A 204
VAL A 170
TYR A 192
 AQD  A1201 (-4.4A)
AQD  A1201 ( 3.9A)
OLA  A1209 ( 4.0A)
None
None
 1.31A 1z9hA-5wivA:
2.2		 1z9hA-5wivA:
21.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z9H_B_IMNB381_1
(MEMBRANE-ASSOCIATED
PROSTAGLANDIN E
SYNTHASE-2)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		5 / 12 THR A 120
CYH A 119
PRO A 204
VAL A 170
TYR A 192
 AQD  A1201 (-4.4A)
AQD  A1201 ( 3.9A)
OLA  A1209 ( 4.0A)
None
None
 1.31A 1z9hB-5wivA:
undetectable		 1z9hB-5wivA:
21.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z9H_C_IMNC379_1
(MEMBRANE-ASSOCIATED
PROSTAGLANDIN E
SYNTHASE-2)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		5 / 12 THR A 120
CYH A 119
PRO A 204
VAL A 170
TYR A 192
 AQD  A1201 (-4.4A)
AQD  A1201 ( 3.9A)
OLA  A1209 ( 4.0A)
None
None
 1.31A 1z9hC-5wivA:
2.2		 1z9hC-5wivA:
21.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Y00_A_Y00A601_1
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		6 / 12 ASP A 115
VAL A 116
SER A 196
PHE A 410
PHE A 411
TYR A 438
 AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-2.8A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
 1.05A 2y00A-5wivA:
29.9		 2y00A-5wivA:
32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Y00_A_Y00A601_1
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		6 / 12 ASP A 115
VAL A 116
SER A 196
PHE A 410
PHE A 411
TYR A 438
 AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-2.8A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
 1.16A 2y00A-5wivA:
29.9		 2y00A-5wivA:
32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Y00_A_Y00A601_1
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		6 / 12 ASP A 115
VAL A 116
SER A 200
PHE A 410
PHE A 411
TYR A 438
 AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-3.6A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
 0.76A 2y00A-5wivA:
29.9		 2y00A-5wivA:
32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Y00_A_Y00A601_1
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		5 / 12 VAL A  92
ASP A 115
SER A 196
PHE A 410
PHE A 411
 PEG  A1218 ( 4.6A)
AQD  A1201 (-3.3A)
AQD  A1201 (-2.8A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
 1.08A 2y00A-5wivA:
29.9		 2y00A-5wivA:
32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Y00_A_Y00A601_1
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		5 / 12 VAL A  92
ASP A 115
SER A 200
PHE A 410
PHE A 411
 PEG  A1218 ( 4.6A)
AQD  A1201 (-3.3A)
AQD  A1201 (-3.6A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
 1.22A 2y00A-5wivA:
29.9		 2y00A-5wivA:
32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Y00_B_Y00B601_1
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		6 / 12 ASP A 115
VAL A 116
SER A 196
PHE A 410
PHE A 411
TYR A 438
 AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-2.8A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
 1.03A 2y00B-5wivA:
29.7		 2y00B-5wivA:
32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Y00_B_Y00B601_1
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		6 / 12 ASP A 115
VAL A 116
SER A 196
PHE A 410
PHE A 411
TYR A 438
 AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-2.8A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
 1.19A 2y00B-5wivA:
29.7		 2y00B-5wivA:
32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Y00_B_Y00B601_1
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		6 / 12 ASP A 115
VAL A 116
SER A 200
PHE A 410
PHE A 411
TYR A 438
 AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-3.6A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
 0.79A 2y00B-5wivA:
29.7		 2y00B-5wivA:
32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Y00_B_Y00B601_1
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		5 / 12 VAL A  92
ASP A 115
SER A 196
PHE A 410
PHE A 411
 PEG  A1218 ( 4.6A)
AQD  A1201 (-3.3A)
AQD  A1201 (-2.8A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
 1.14A 2y00B-5wivA:
29.7		 2y00B-5wivA:
32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Y00_B_Y00B601_1
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		5 / 12 VAL A  92
ASP A 115
SER A 200
PHE A 410
PHE A 411
 PEG  A1218 ( 4.6A)
AQD  A1201 (-3.3A)
AQD  A1201 (-3.6A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
 1.25A 2y00B-5wivA:
29.7		 2y00B-5wivA:
32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Y01_A_Y00A601_1
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		5 / 12 ASP A 115
SER A 196
PHE A 410
PHE A 411
VAL A 430
 AQD  A1201 (-3.3A)
AQD  A1201 (-2.8A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
 1.42A 2y01A-5wivA:
29.7		 2y01A-5wivA:
32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Y01_B_Y00B601_1
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		6 / 12 ASP A 115
VAL A 116
SER A 196
PHE A 410
PHE A 411
TYR A 438
 AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-2.8A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
 1.05A 2y01B-5wivA:
29.6		 2y01B-5wivA:
32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Y01_B_Y00B601_1
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		6 / 12 ASP A 115
VAL A 116
SER A 196
PHE A 410
PHE A 411
TYR A 438
 AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-2.8A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
 1.19A 2y01B-5wivA:
29.6		 2y01B-5wivA:
32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Y01_B_Y00B601_1
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		6 / 12 ASP A 115
VAL A 116
SER A 200
PHE A 410
PHE A 411
TYR A 438
 AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-3.6A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
 0.78A 2y01B-5wivA:
29.6		 2y01B-5wivA:
32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Y01_B_Y00B601_1
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		5 / 12 LEU A  90
ASP A 115
VAL A 116
SER A 196
TYR A 438
 None
AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-2.8A)
None
 1.16A 2y01B-5wivA:
29.6		 2y01B-5wivA:
32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Y01_B_Y00B601_1
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		6 / 12 VAL A  92
ASP A 115
VAL A 116
SER A 196
PHE A 410
PHE A 411
 PEG  A1218 ( 4.6A)
AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-2.8A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
 1.19A 2y01B-5wivA:
29.6		 2y01B-5wivA:
32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Y01_B_Y00B601_1
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		6 / 12 VAL A  92
ASP A 115
VAL A 116
SER A 200
PHE A 410
PHE A 411
 PEG  A1218 ( 4.6A)
AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-3.6A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
 1.18A 2y01B-5wivA:
29.6		 2y01B-5wivA:
32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Y03_A_5FWA601_1
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		6 / 12 ASP A 115
VAL A 116
SER A 196
PHE A 410
PHE A 411
TYR A 438
 AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-2.8A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
 1.01A 2y03A-5wivA:
29.6		 2y03A-5wivA:
32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Y03_A_5FWA601_1
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		6 / 12 ASP A 115
VAL A 116
SER A 196
PHE A 410
PHE A 411
TYR A 438
 AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-2.8A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
 1.16A 2y03A-5wivA:
29.6		 2y03A-5wivA:
32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Y03_A_5FWA601_1
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		6 / 12 ASP A 115
VAL A 116
SER A 200
PHE A 410
PHE A 411
TYR A 438
 AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-3.6A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
 0.83A 2y03A-5wivA:
29.6		 2y03A-5wivA:
32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Y03_B_5FWB601_1
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		6 / 12 ASP A 115
VAL A 116
SER A 196
PHE A 410
PHE A 411
TYR A 438
 AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-2.8A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
 0.97A 2y03B-5wivA:
29.7		 2y03B-5wivA:
32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Y03_B_5FWB601_1
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		6 / 12 ASP A 115
VAL A 116
SER A 196
PHE A 410
PHE A 411
TYR A 438
 AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-2.8A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
 1.15A 2y03B-5wivA:
29.7		 2y03B-5wivA:
32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Y03_B_5FWB601_1
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		6 / 12 ASP A 115
VAL A 116
SER A 200
PHE A 410
PHE A 411
TYR A 438
 AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-3.6A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
 0.79A 2y03B-5wivA:
29.7		 2y03B-5wivA:
32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Y04_A_68HA601_1
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		7 / 11 ASP A 115
VAL A 116
SER A 196
SER A 200
PHE A 410
PHE A 411
TYR A 438
 AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-2.8A)
AQD  A1201 (-3.6A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
 0.86A 2y04A-5wivA:
29.5		 2y04A-5wivA:
32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Y04_B_68HB601_1
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		7 / 12 ASP A 115
VAL A 116
SER A 196
SER A 200
PHE A 410
PHE A 411
TYR A 438
 AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-2.8A)
AQD  A1201 (-3.6A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
 0.81A 2y04B-5wivA:
29.5		 2y04B-5wivA:
32.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3D4S_A_TIMA401_1
(BETA-2 ADRENERGIC
RECEPTOR/T4-LYSOZYME
CHIMERA)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		6 / 12 ASP A 115
VAL A 116
SER A 196
TRP A 407
PHE A 411
TYR A 438
 AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-2.8A)
None
AQD  A1201 (-4.6A)
None
 0.74A 3d4sA-5wivA:
30.4		 3d4sA-5wivA:
27.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3D4S_A_TIMA401_2
(BETA-2 ADRENERGIC
RECEPTOR/T4-LYSOZYME
CHIMERA)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		3 / 3 THR A 120
SER A 200
PHE A 410
 AQD  A1201 (-4.4A)
AQD  A1201 (-3.6A)
AQD  A1201 (-4.7A)
 0.64A 3d4sA-5wivA:
30.4		 3d4sA-5wivA:
27.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		6 / 12 ASP A 115
VAL A 116
SER A 196
PHE A 410
PHE A 411
TYR A 438
 AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-2.8A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
 1.15A 3nyaA-5wivA:
30.1		 3nyaA-5wivA:
27.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3NYA_A_JTZA1203_1
(BETA-2 ADRENERGIC
RECEPTOR, LYSOZYME)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		7 / 12 ASP A 115
VAL A 116
SER A 196
SER A 200
PHE A 410
PHE A 411
TYR A 438
 AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-2.8A)
AQD  A1201 (-3.6A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
 0.84A 3nyaA-5wivA:
30.1		 3nyaA-5wivA:
27.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RZE_A_D7VA1201_1
(HISTAMINE H1
RECEPTOR, LYSOZYME
CHIMERA)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		6 / 12 ASP A 115
THR A 120
ILE A 123
TRP A 407
PHE A 411
TYR A 438
 AQD  A1201 (-3.3A)
AQD  A1201 (-4.4A)
None
None
AQD  A1201 (-4.6A)
None
 0.66A 3rzeA-5wivA:
28.4		 3rzeA-5wivA:
28.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_A_CVDA1359_1
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		5 / 12 ASP A 115
VAL A 116
SER A 196
PHE A 411
TYR A 438
 AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-2.8A)
AQD  A1201 (-4.6A)
None
 1.20A 4amjA-5wivA:
29.7		 4amjA-5wivA:
32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_A_CVDA1359_1
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		8 / 12 ASP A 115
VAL A 116
SER A 196
SER A 200
TRP A 407
PHE A 410
PHE A 411
TYR A 438
 AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-2.8A)
AQD  A1201 (-3.6A)
None
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
 0.81A 4amjA-5wivA:
29.7		 4amjA-5wivA:
32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_A_CVDA1359_1
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		5 / 12 ASP A 115
VAL A 116
SER A 200
PHE A 410
PHE A 411
 AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-3.6A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
 1.50A 4amjA-5wivA:
29.7		 4amjA-5wivA:
32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_B_CVDB1360_1
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		7 / 12 ASP A 115
SER A 196
SER A 200
TRP A 407
PHE A 410
PHE A 411
TYR A 438
 AQD  A1201 (-3.3A)
AQD  A1201 (-2.8A)
AQD  A1201 (-3.6A)
None
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
 0.80A 4amjB-5wivA:
29.7		 4amjB-5wivA:
32.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AQL_A_TXCA1452_2
(GUANINE DEAMINASE)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		4 / 5 HIS A 414
LEU A 118
LEU A  88
ASP A  80
 AQD  A1201 (-4.0A)
None
None
NA  A1224 (-3.2A)
 1.23A 4aqlA-5wivA:
undetectable		 4aqlA-5wivA:
20.49
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4IAQ_A_2GMA2001_1
(CHIMERA PROTEIN OF
HUMAN
5-HYDROXYTRYPTAMINE
RECEPTOR 1B AND E.
COLI SOLUBLE
CYTOCHROME B562)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		5 / 12 ASP A 115
TRP A 407
PHE A 410
PHE A 411
THR A 434
 AQD  A1201 (-3.3A)
None
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
AQD  A1201 (-3.5A)
 0.61A 4iaqA-5wivA:
32.5		 4iaqA-5wivA:
49.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LDO_A_ALEA1402_1
(LYSOZYME, BETA-2
ADRENERGIC RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		5 / 10 ASP A 115
VAL A 116
SER A 196
PHE A 410
TYR A 438
 AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-2.8A)
AQD  A1201 (-4.7A)
None
 0.91A 4ldoA-5wivA:
27.3		 4ldoA-5wivA:
27.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LDO_A_ALEA1402_1
(LYSOZYME, BETA-2
ADRENERGIC RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		5 / 10 ASP A 115
VAL A 116
SER A 200
PHE A 410
TYR A 438
 AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-3.6A)
AQD  A1201 (-4.7A)
None
 0.69A 4ldoA-5wivA:
27.3		 4ldoA-5wivA:
27.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		7 / 12 THR A 120
ILE A 123
PHE A 403
TRP A 407
PHE A 410
PHE A 411
TYR A 438
 AQD  A1201 (-4.4A)
None
None
None
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
 0.78A 6a93A-5wivA:
34.4		 6a93A-5wivA:
44.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		5 / 12 VAL A 116
THR A 120
TRP A 407
PHE A 410
PHE A 411
 AQD  A1201 ( 3.9A)
AQD  A1201 (-4.4A)
None
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
 0.72A 6a93B-5wivA:
34.8		 6a93B-5wivA:
44.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		4 / 5 ASP A 115
ILE A 123
PHE A 403
TYR A 438
 AQD  A1201 (-3.3A)
None
None
None
 0.41A 6a93B-5wivA:
34.7		 6a93B-5wivA:
44.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6A94_A_ZOTA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		7 / 12 LEU A 187
VAL A 193
SER A 200
PHE A 403
TRP A 407
PHE A 410
PHE A 411
 AQD  A1201 (-4.5A)
AQD  A1201 (-3.9A)
AQD  A1201 (-3.6A)
None
None
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
 0.67A 6a94A-5wivA:
31.5		 6a94A-5wivA:
44.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6A94_B_ZOTB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		9 / 12 VAL A 116
THR A 120
LEU A 187
VAL A 193
SER A 200
PHE A 403
TRP A 407
PHE A 410
PHE A 411
 AQD  A1201 ( 3.9A)
AQD  A1201 (-4.4A)
AQD  A1201 (-4.5A)
AQD  A1201 (-3.9A)
AQD  A1201 (-3.6A)
None
None
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
 0.83A 6a94B-5wivA:
34.6		 6a94B-5wivA:
44.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6CM4_A_8NUA2001_0
(D(2) DOPAMINE
RECEPTOR, ENDOLYSIN
CHIMERA)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		5 / 12 CYH A 119
THR A 120
SER A 197
TRP A 407
THR A 434
 AQD  A1201 ( 3.9A)
AQD  A1201 (-4.4A)
AQD  A1201 ( 4.0A)
None
AQD  A1201 (-3.5A)
 1.31A 6cm4A-5wivA:
30.5		 6cm4A-5wivA:
35.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6CM4_A_8NUA2001_0
(D(2) DOPAMINE
RECEPTOR, ENDOLYSIN
CHIMERA)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		5 / 12 THR A 120
SER A 197
PHE A 403
TRP A 407
THR A 434
 AQD  A1201 (-4.4A)
AQD  A1201 ( 4.0A)
None
None
AQD  A1201 (-3.5A)
 1.00A 6cm4A-5wivA:
30.5		 6cm4A-5wivA:
35.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6CM4_A_8NUA2001_0
(D(2) DOPAMINE
RECEPTOR, ENDOLYSIN
CHIMERA)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		5 / 12 VAL A 116
CYH A 119
THR A 120
TRP A 407
THR A 434
 AQD  A1201 ( 3.9A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-4.4A)
None
AQD  A1201 (-3.5A)
 1.14A 6cm4A-5wivA:
30.5		 6cm4A-5wivA:
35.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6CM4_A_8NUA2001_0
(D(2) DOPAMINE
RECEPTOR, ENDOLYSIN
CHIMERA)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		6 / 12 VAL A 116
PHE A 403
TRP A 407
PHE A 411
THR A 434
TYR A 438
 AQD  A1201 ( 3.9A)
None
None
AQD  A1201 (-4.6A)
AQD  A1201 (-3.5A)
None
 0.68A 6cm4A-5wivA:
30.5		 6cm4A-5wivA:
35.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6CM4_A_8NUA2001_0
(D(2) DOPAMINE
RECEPTOR, ENDOLYSIN
CHIMERA)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		5 / 12 VAL A 116
SER A 196
PHE A 403
TRP A 407
PHE A 411
 AQD  A1201 ( 3.9A)
AQD  A1201 (-2.8A)
None
None
AQD  A1201 (-4.6A)
 1.12A 6cm4A-5wivA:
30.5		 6cm4A-5wivA:
35.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6CM4_A_8NUA2001_0
(D(2) DOPAMINE
RECEPTOR, ENDOLYSIN
CHIMERA)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		6 / 12 VAL A 116
THR A 120
PHE A 403
TRP A 407
THR A 434
TYR A 438
 AQD  A1201 ( 3.9A)
AQD  A1201 (-4.4A)
None
None
AQD  A1201 (-3.5A)
None
 0.40A 6cm4A-5wivA:
30.5		 6cm4A-5wivA:
35.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6DRX_A_H8GA1201_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		5 / 12 VAL A 116
THR A 120
TRP A 407
PHE A 410
TYR A 438
 AQD  A1201 ( 3.9A)
AQD  A1201 (-4.4A)
None
AQD  A1201 (-4.7A)
None
 0.73A 6drxA-5wivA:
28.4		 6drxA-5wivA:
51.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6DRY_A_H8DA2001_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		6 / 11 ASP A 115
VAL A 116
THR A 120
LEU A 187
PHE A 410
TYR A 438
 AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-4.4A)
AQD  A1201 (-4.5A)
AQD  A1201 (-4.7A)
None
 0.84A 6dryA-5wivA:
30.8		 6dryA-5wivA:
50.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6DRZ_A_H8JA1206_0
(5HT2B RECEPTOR, BRIL
CHIMERA)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		6 / 12 VAL A 116
THR A 120
LEU A 187
PHE A 410
PHE A 411
TYR A 438
 AQD  A1201 ( 3.9A)
AQD  A1201 (-4.4A)
AQD  A1201 (-4.5A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
 0.76A 6drzA-5wivA:
30.8		 6drzA-5wivA:
50.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6H7J_A_5FWA401_0
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		7 / 12 ASP A 115
VAL A 116
SER A 196
SER A 197
PHE A 410
PHE A 411
TYR A 438
 AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-2.8A)
AQD  A1201 ( 4.0A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
 0.89A 6h7jA-5wivA:
27.1		 6h7jA-5wivA:
15.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6H7J_A_5FWA401_0
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		6 / 12 ASP A 115
VAL A 116
SER A 197
SER A 196
PHE A 410
PHE A 411
 AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 ( 4.0A)
AQD  A1201 (-2.8A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
 1.33A 6h7jA-5wivA:
27.1		 6h7jA-5wivA:
15.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6H7J_A_5FWA401_0
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		7 / 12 ASP A 115
VAL A 116
SER A 197
SER A 200
PHE A 410
PHE A 411
TYR A 438
 AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 ( 4.0A)
AQD  A1201 (-3.6A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
 0.67A 6h7jA-5wivA:
27.1		 6h7jA-5wivA:
15.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6H7J_B_5FWB402_0
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		7 / 12 ASP A 115
VAL A 116
SER A 196
SER A 197
PHE A 410
PHE A 411
TYR A 438
 AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-2.8A)
AQD  A1201 ( 4.0A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
 0.88A 6h7jB-5wivA:
27.6		 6h7jB-5wivA:
15.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6H7J_B_5FWB402_0
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		6 / 12 ASP A 115
VAL A 116
SER A 197
SER A 196
PHE A 410
PHE A 411
 AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 ( 4.0A)
AQD  A1201 (-2.8A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
 1.33A 6h7jB-5wivA:
27.6		 6h7jB-5wivA:
15.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6H7J_B_5FWB402_0
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		7 / 12 ASP A 115
VAL A 116
SER A 197
SER A 200
PHE A 410
PHE A 411
TYR A 438
 AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 ( 4.0A)
AQD  A1201 (-3.6A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
 0.67A 6h7jB-5wivA:
27.6		 6h7jB-5wivA:
15.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6H7M_A_68HA504_0
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		5 / 12 ASP A 115
SER A 196
PHE A 410
PHE A 411
TYR A 438
 AQD  A1201 (-3.3A)
AQD  A1201 (-2.8A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
 0.97A 6h7mA-5wivA:
27.0		 6h7mA-5wivA:
15.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6H7M_A_68HA504_0
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		5 / 12 ASP A 115
VAL A 116
SER A 196
PHE A 410
PHE A 411
 AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-2.8A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
 1.32A 6h7mA-5wivA:
27.0		 6h7mA-5wivA:
15.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6H7M_A_68HA504_0
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		6 / 12 ASP A 115
VAL A 116
SER A 200
PHE A 410
PHE A 411
TYR A 438
 AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-3.6A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
 0.72A 6h7mA-5wivA:
27.0		 6h7mA-5wivA:
15.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6H7M_B_68HB405_0
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		5 / 12 ASP A 115
SER A 196
PHE A 410
PHE A 411
TYR A 438
 AQD  A1201 (-3.3A)
AQD  A1201 (-2.8A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
 0.97A 6h7mB-5wivA:
27.2		 6h7mB-5wivA:
15.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6H7M_B_68HB405_0
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		5 / 12 ASP A 115
VAL A 116
SER A 196
PHE A 410
PHE A 411
 AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-2.8A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
 1.32A 6h7mB-5wivA:
27.2		 6h7mB-5wivA:
15.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6H7M_B_68HB405_0
(BETA-1 ADRENERGIC
RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		6 / 12 ASP A 115
VAL A 116
SER A 200
PHE A 410
PHE A 411
TYR A 438
 AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-3.6A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
 0.72A 6h7mB-5wivA:
27.2		 6h7mB-5wivA:
15.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6IBL_A_H98A501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		5 / 12 VAL A 116
TRP A 407
PHE A 410
PHE A 411
TYR A 438
 AQD  A1201 ( 3.9A)
None
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
 0.53A 6iblA-5wivA:
26.9		 6iblA-5wivA:
30.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6IBL_A_H98A501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		5 / 12 VAL A 116
TRP A 407
PHE A 410
PHE A 411
VAL A 430
 AQD  A1201 ( 3.9A)
None
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
 1.26A 6iblA-5wivA:
26.9		 6iblA-5wivA:
30.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6IBL_B_H98B501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		5 / 12 VAL A 116
TRP A 407
PHE A 410
PHE A 411
TYR A 438
 AQD  A1201 ( 3.9A)
None
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
 0.57A 6iblB-5wivA:
26.9		 6iblB-5wivA:
30.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6IBL_B_H98B501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		 5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens) 		5 / 12 VAL A 116
TRP A 407
PHE A 410
PHE A 411
VAL A 430
 AQD  A1201 ( 3.9A)
None
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
 1.28A 6iblB-5wivA:
26.9		 6iblB-5wivA:
30.64